Molecular basis of resistance to proteasome inhibitors in hematological malignancies.

  title={Molecular basis of resistance to proteasome inhibitors in hematological malignancies.},
  author={Denise Niewerth and Gerrit Jansen and Yehuda G Assaraf and Sonja Zweegman and Gertjan J L Kaspers and Jacqueline Cloos},
  journal={Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy},
Over the past decade, the proteasome inhibitor bortezomib (Velcade) has not only gained a cornerstone position in the treatment of hematological malignancies, particularly multiple myeloma and mantle cell lymphoma, but also in experimental therapeutics of acute leukemia. However, the therapeutic efficacy of bortezomib is hampered by the emergence of acquired resistance, for which multifactorial mechanisms have been identified. This review summarizes the current status of the molecular… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
31 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 31 extracted citations

Similar Papers

Loading similar papers…